Alphatec

Q2 FY2026 EarningsQ3 FY26 results presented a mixed profile: total revenue of $221.2M missed the $225.1M consensus, primarily due to lower biologics attachment. However, Non-GAAP EPS of $0.09 was in-line with expectations, and GAAP net loss of -$0.03 per share significantly beat the consensus of -$0.11 due to lower-than-expected operating and interest expenses. While surgical hardware grew 17% YoY, management lowered FY26 revenue guidance to ~$862M (vs. previous expectations of higher growth), while maintaining a focus on Adjusted EBITDA profitability.